Pulmonary fibrosis, a chronic and progressive interstitial lung disease, seriously affects respiratory function and can be life-threatening due to complications such as acute respiratory deterioration, acute coronary syndromes, congestive heart failure, lung cancer, infections, and venous thrombosis. With around 3.4 million patients and 100,000 new cases each year in China, idiopathic pulmonary fibrosis (IPF) has a median survival of 2-3 years and a 5-year survival rate below 30%, lower than many cancers, hence the name "a cancer-like disease."
Recently, the internationally renowned translational medical journal Bioengineering & Translational Medicine (JCR Q1, IF=10.684) published a research paper titled "Macrophage-based delivery of anti-fibrotic proteins alleviates bleomycin-induced pulmonary fibrosis in mice." This project, a joint effort by RocRock Bio, the General Hospital of the Chinese People's Liberation Army, Shenyang University of Chemical Technology, and Shenzhen General Hospital, used RocRock Bio's Del-M technology platform to achieve the application of engineered macrophage - based protein delivery technology in treating mouse models of pulmonary fibrosis, with promising results. RocRock Bio is the corresponding author unit, and Dr. Xiushan Yin, the founder and CEO of RocRock Bio, is the Corresponding Author. The publication of these findings highlights the depth of RocRock Bio's research and development capabilities in engineered macrophage technology, enriches its R&D pipeline, and shows the promising translational prospects of the Del-M technology platform in chronic disease cell therapy.